H.C. Wainwright reiterates Buy rating on Evaxion Biotech stock with $16 target
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Evaxion Biotech, setting a target price of $16 for the stock. This endorsement highlights the firm's confidence in Evaxion's potential for growth and innovation in the biotech sector, which is crucial for investors looking for promising opportunities in healthcare.
— Curated by the World Pulse Now AI Editorial System